investordatabase.org

Aescap Life Sciences

aescap.com Direct investor

Aescap Life Sciences is an investment firm that manages two public biotech funds, investing in listed biotech and life sciences companies with a focus on high-conviction portfolios and AI-driven medical innovation.

Aescap Life Sciences is an asset manager headquartered in Amsterdam, Netherlands, founded in 2005. It invests directly in companies, at growth, in biotech, life sciences, genetics and gene therapy. €182M under management and 40 portfolio companies, as it reports.

“The Aescap funds focus on biotech companies leading the application of AI in research and development.”

Aescap Life Sciences, own website
Layer
Direct investor
Type
Asset manager
Stage
Growth
Headquarters
Amsterdam, Netherlands
Sectors
biotech, life sciences, genetics, gene therapy, RNA therapy, cell therapy
Founded
2005
Assets under management
€182M
Portfolio
40 companies

Team, as Aescap Life Sciences publishes it

  • Patrick Krol Founder & Portfolio Manager
  • Victor Bakker Head of Investor Relations
  • Paolo del Bufalo Investment Manager
  • Pien Kiliaan Senior Analyst
  • Natalie Santagostino Analyst
  • Lincoln Lukose Head of AI Research & Intelligence
  • Sam Frenay Quantitative Strategist
  • Nicole Scatton Quantitative researcher
  • Gert Hoogland Portfolio Advisor
  • Maarten Hendriks Portfolio Advisor
  • Peter Hintzen Portfolio Advisor

Names and roles exactly as listed on aescap.com. Nothing else about these people is recorded.

Where this comes from

Every fact above was read from a page Aescap Life Sciences publishes itself. Nothing is taken from third-party databases. Investment activity (deals, co-investors) is not yet recorded.

Is this record wrong or stale? Report a mistake — it reaches us directly, no email address to look up.

Record 1196 · added 2026-08-28 · link last verified 2026-09-06 · confidence high

Similar investors

Listed under